Changes in fetal DNA modification associated with maternal blood sugar during pregnancy

2017 ◽  
Author(s):  
Angela Estampador ◽  
Paul Franks
2010 ◽  
Vol 36 (S1) ◽  
pp. 221-221
Author(s):  
R. Vlk ◽  
I. Hromadnikova ◽  
M. Simandlova ◽  
M. Hrehorcak ◽  
M. Havlovicova ◽  
...  
Keyword(s):  

2014 ◽  
Vol 34 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Jacob Mørup Schlütter ◽  
Lotte Hatt ◽  
Cathrine Bach ◽  
Ida Kirkegaard ◽  
Steen Kølvraa ◽  
...  

1955 ◽  
Vol 18 (4) ◽  
pp. 553-554 ◽  
Author(s):  
Jørgen Pedersen

SUMMARY Birth weight and length of 122 surviving babies of diabetics, born in Rigshospitalet, Copenhagen 1926–1947, was compared to a control group of 122 infants of non-diabetics (matched controls). The groups were comparable, especially as to foetal age and parity of the mother, severe complications in the mothers, etc. The average foetal age was 261 days (range 237–301). The average weight and length for the infants of non-diab. controls was 3045 gm. and 49.5 cm., for infants of diabetics 3600 gm. and 51.0 cm. Thus on average infants of diabetics weigh 550 gm. more and are 1.5 cm. longer than are infants of non-diab. Differences of the same magnitude were found in primiparae and in multiparae with and without obesity. The frequency distribution curves for weight and length are nearly normal, but placed at higher levels than are those of non-diab. infants. Diabetics get big and small infants as others, but the whole population is bigger than that of non-diabetics' infants. There is an actual overgrowth. In a personal series from 1946–1953 75 infants of long-term treated (1. t.) were compared to 91 infants of short-term treated (sh. t.) diabetics. The foetal age was 237 days or more, on average 260 days. Average weight and length for 1. t. infants was 3380 gm. and 50.5 cm., for sh. t. 3570 gm. and 51.3 cm. Thus the 1. t. infants on average weighed 190 gm. less and were 0.8 cm. shorter than sh. t. infants. So far these differences are not statistically significant, but an inverse correlation between the length of the last consecutive stay of the mother in Department B and the infants' weight and length could be demon I. Published in extenso in Acta endocrinol. 16, 330, 1954. strated. As the length of stay increases, weight and length decreases. This indicates the differences found to be due to the length of our treatment. As there is a positive correlation between the maternal pregnancy level of blood sugar (foetal glucose supply) during the last 6–7 weeks of pregnancy and the birth weight and length of infants of non-diabetic controls, 1. t. and sh. t. diabetics, the maternal pregnancy level may play a part of its own for the differences found in weight and length of the infants in these 3 groups. The maternal blood sugar level may influence weight and length of the infants directly (foetal glucose consumption) but also indirectly (foetal insulin turn-over rising with a rising supply of glucose), as foetal insulin may act as a growth stimulating factor.


2010 ◽  
Vol 56 (1) ◽  
pp. 90-98 ◽  
Author(s):  
Yu K Tong ◽  
Shengnan Jin ◽  
Rossa WK Chiu ◽  
Chunming Ding ◽  
KC Allen Chan ◽  
...  

Abstract Background: The use of fetal DNA in maternal plasma for noninvasive prenatal diagnosis of trisomy 21 (T21) is an actively researched area. We propose a novel method of T21 detection that combines fetal-specific epigenetic and genetic markers. Methods: We used combined bisulfite restriction analysis to search for fetal DNA markers on chromosome 21 that were differentially methylated in the placenta and maternal blood cells and confirmed any target locus with bisulfite sequencing. We then used methylation-sensitive restriction endonuclease digestion followed by microfluidics digital PCR analysis to investigate the identified marker. Chromosome-dosage analysis was performed by comparing the dosage of this epigenetic marker with that of the ZFY (zinc finger protein, Y-linked) gene on chromosome Y. Results: The putative promoter of the HLCS (holocarboxylase synthetase) gene was hypermethylated in the placenta and hypomethylated in maternal blood cells. A chromosome-dosage comparison of the hypermethylated HLCS and ZFY loci could distinguish samples of T21 and euploid placental DNA. Twenty-four maternal plasma samples from euploid pregnancies and 5 maternal plasma samples from T21 pregnancies were analyzed. All but 1 of the euploid samples were correctly classified. Conclusions: The epigenetic–genetic chromosome-dosage approach is a new method for noninvasive prenatal detection of T21. The epigenetic part of the analysis can be applied to all pregnancies. Because the genetic part of the analysis uses paternally inherited, fetal-specific genetic markers that are abundant in the genome, broad population coverage should be readily achievable. This approach has the potential to become a generally usable technique for noninvasive prenatal diagnosis.


2004 ◽  
Vol 58 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Xiao Xi Zhao ◽  
Nobuhiro Suzumori ◽  
Yasuhiko Ozaki ◽  
Takeshi Sato ◽  
Kaoru Suzumori

2016 ◽  
Vol 5 (2) ◽  
pp. 89 ◽  
Author(s):  
I Nyoman Hariyasa Sanjaya ◽  
Tjok Gde Agung Suwardewa ◽  
I G Kamasan N. Arijana

2012 ◽  
Vol 36 (5) ◽  
Author(s):  
Markus Stumm ◽  
Rolf-Dieter Wegner ◽  
Wera Hofmann

ZusammenfassungDie zellfreie fetale DNA (cff-DNA) im mütterlichen Blut bietet viele neue Möglichkeiten der pränatalen genetischen Diagnostik. Im Gegensatz zu den etablierten invasiven Techniken der Chorionzottenbiopsie (CVS) und der Amniozentese (AC), die beide mit einem spezifischen Risiko (0,5–1%) einer eingriffsbedingten Fehlgeburt einhergehen, ist die Grundlage für die Gewinnung der cff-DNA eine einfache venöse Blutentnahme der Mutter, die keinerlei Risiko für den Embryo oder Feten darstellt. Damit bietet die cff-DNA die Möglichkeit einer risikofreien genetischen Diagnostik von bestehenden Schwangerschaften. Molekulargenetische Techniken werden schon seit längerer Zeit zum qualitativen Nachweis von spezifischen fetalen Sequenzen, wie paternal vererbten oder neu entstandenen (de novo) Mutationen, eingesetzt. Durch den Einsatz digitaler PCR und Next-Generation-Sequencing (NGS) Technologien gelingt mittlerweile aber auch der sichere quantitative Nachweis von mutierten Allelen sowie von klinisch relevanten Aneuploidien (Trisomie 13, 18 und 21) aus fetaler DNA im mütterlichen Blut.


Sign in / Sign up

Export Citation Format

Share Document